Frank J Edwards1, Robert Wicelinski2, Nicholas Gallagher2, Alice McKinzie3, Ryan White3, Ann Domingos4. 1. Department of Emergency Medicine, Arnot Ogden Medical Center, Elmira, NY. Electronic address: fedwardsmd@gmail.com. 2. Department of Emergency Medicine, Arnot Ogden Medical Center, Elmira, NY. 3. Department of Psychiatry, Arnot Ogden Medical Center, Elmira, NY. 4. CASA-Trinity Substance and Alcohol Treatment Center, Elmira, NY.
Abstract
STUDY OBJECTIVE: We assess the feasibility of using our community hospital emergency department (ED) as an immediate portal to medication-assisted treatment for patients in opioid withdrawal. METHODS: This was a prospective observational cohort study. In collaboration with an outpatient substance abuse treatment center, we alerted the public through media outlets that individuals could receive immediate buprenorphine treatment for opioid withdrawal in the ED, with rapid referral for medication-assisted treatment. If medication-assisted treatment intake was delayed, patients could return for up to 2 more days for buprenorphine administration to treat their withdrawal symptoms. We measured compliance with initial follow-up and continued treatment engagement at 30 and 90 days. RESULTS: The study was conducted during 12 months. A total of 62 patients were enrolled, evaluated for buprenorphine criteria, and referred for medication-assisted treatment. Fifty subjects were compliant with their first medication-assisted treatment follow-up visit (81% [95% confidence interval 71% to 91%]), and 43 of these 50 patients were still engaged in medication-assisted treatment at 30 days (86% [95% confidence interval 76% to 96%]), with 33 of the 50 still engaged at 90 days (66% [95% confidence interval 53% to 79%]). We observed no instances of precipitated withdrawal or other adverse reactions in the ED. CONCLUSION: A substantial number of patients responded to this program and received accelerated engagement in medication-assisted treatment. Such a program is feasible in the community hospital ED and may prevent some individuals from relapsing into high-risk illicit drug use when immediate medication-assisted treatment is not otherwise available.
STUDY OBJECTIVE: We assess the feasibility of using our community hospital emergency department (ED) as an immediate portal to medication-assisted treatment for patients in opioid withdrawal. METHODS: This was a prospective observational cohort study. In collaboration with an outpatient substance abuse treatment center, we alerted the public through media outlets that individuals could receive immediate buprenorphine treatment for opioid withdrawal in the ED, with rapid referral for medication-assisted treatment. If medication-assisted treatment intake was delayed, patients could return for up to 2 more days for buprenorphine administration to treat their withdrawal symptoms. We measured compliance with initial follow-up and continued treatment engagement at 30 and 90 days. RESULTS: The study was conducted during 12 months. A total of 62 patients were enrolled, evaluated for buprenorphine criteria, and referred for medication-assisted treatment. Fifty subjects were compliant with their first medication-assisted treatment follow-up visit (81% [95% confidence interval 71% to 91%]), and 43 of these 50 patients were still engaged in medication-assisted treatment at 30 days (86% [95% confidence interval 76% to 96%]), with 33 of the 50 still engaged at 90 days (66% [95% confidence interval 53% to 79%]). We observed no instances of precipitated withdrawal or other adverse reactions in the ED. CONCLUSION: A substantial number of patients responded to this program and received accelerated engagement in medication-assisted treatment. Such a program is feasible in the community hospital ED and may prevent some individuals from relapsing into high-risk illicit drug use when immediate medication-assisted treatment is not otherwise available.
Authors: Margaret Lowenstein; Jeanmarie Perrone; Ruiying A Xiong; Christopher K Snider; Nicole O'Donnell; Davis Hermann; Roy Rosin; Julie Dees; Rachel McFadden; Utsha Khatri; Zachary F Meisel; Nandita Mitra; M Kit Delgado Journal: Ann Emerg Med Date: 2021-12-23 Impact factor: 5.721
Authors: Elizabeth M Schoenfeld; Lauren M Westafer; Samantha A Beck; Benjamin G Potee; Sravanthi Vysetty; Caty Simon; Jillian M Tozloski; Abigail L Girardin; William E Soares Journal: Acad Emerg Med Date: 2022-05-16 Impact factor: 5.221
Authors: Gillian A Beauchamp; Lexis T Laubach; Samantha B Esposito; Ali Yazdanyar; Paige Roth; Priyanka Lauber; Jamie Allen; Nathan Boateng; Samantha Shaak; David B Burmeister Journal: J Med Toxicol Date: 2020-11-04
Authors: Clara Z Guo; Gail D'Onofrio; David A Fiellin; E Jennifer Edelman; Kathryn Hawk; Andrew Herring; Ryan McCormack; Jeanmarie Perrone; Ethan Cowan Journal: J Am Coll Emerg Physicians Open Date: 2021-11-29